R
Ross A. Baker
Researcher at Princeton University
Publications - 120
Citations - 22644
Ross A. Baker is an academic researcher from Princeton University. The author has contributed to research in topics: Aripiprazole & Brexpiprazole. The author has an hindex of 26, co-authored 119 publications receiving 20522 citations. Previous affiliations of Ross A. Baker include Bristol-Myers Squibb.
Papers
More filters
Journal Article
The Mini-International Neuropsychiatric Interview (M.I.N.I.) : The development and validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10
David V. Sheehan,Yves Lecrubier,Kathy Harnett Sheehan,P. Amorim,J. Janavs,Emmanuelle Weiller,T. Hergueta,Ross A. Baker,Dunbar Geoffrey Charles +8 more
TL;DR: The Mini-International Neuropsychiatric Interview is designed to meet the need for a short but accurate structured psychiatric interview for multicenter clinical trials and epidemiology studies and to be used as a first step in outcome tracking in nonresearch clinical settings.
DatasetDOI
Mini International Neuropsychiatric Interview
David V. Sheehan,J. Janavs,Ross A. Baker,K. Harnett-Sheehan,E. Knapp,M. Sheehan,Yves Lecrubier,Emmanuelle Weiller,T. Hergueta,P. Amorim,L. I. Bonora,J. P. Lépine +11 more
Journal ArticleDOI
Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
TL;DR: A comprehensive overview of antipsychotics and hyperprolactinemia is presented together with a review of emerging evidence about the short- and long-term health risks of hyper Prolactin elevation.
Journal ArticleDOI
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study
W. Wolfgang Fleischhacker,Raymond Sanchez,Pamela Perry,Na Jin,Timothy Peters-Strickland,B. Johnson,Ross A. Baker,Anna Eramo,Robert D. McQuade,William H. Carson,David P. Walling,John M. Kane +11 more
TL;DR: Aripiprazole once-monthly 400mg was non-inferior to oral aripipazole, and the reduction in Kaplan–Meier estimated impending relapse rate at week 26 was statistically significant.
Journal ArticleDOI
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Dieter Naber,K. Hansen,Carlos Forray,Ross A. Baker,Christophe Sapin,M. Beillat,Timothy Peters-Strickland,Anna-Greta Nylander,Peter Hertel,Henrik Steen Andersen,Anna Eramo,Jean-Yves Loze,Steven G. Potkin +12 more
TL;DR: In this article, a 28-week, randomized, non-inferiority, open-label, rater-blinded, head-to-head study (QUALIFY) of aripiprazole once-monthly 400mg (AOM 400) and paliperidone palmitate oncemonthly (PP) on the Heinrichs-Carpenter Quality-of-Life Scale (QLS), a validated health-related quality of life and functioning measure in schizophrenia was conducted.